Samer Gawrieh, Bettina G. Papouchado, Lawrence J. Burgart, Shogo Kobayashi, Michael R. Charlton, Gregory J. Gores – 23 September 2005 – Only a subset of hepatitis C virus (HCV)‐infected patients develop progressive hepatic fibrosis after liver transplantation (LT). Hepatic stellate cell (HSC) activation is a pivotal step in hepatic fibrosis and precedes clinically apparent fibrosis. We determined whether early HSC activation, measured in 4‐month protocol post‐LT biopsies, is predictive of subsequent development of more histologically severe recurrence of HCV.

Thomas Longerich, Christoph Eisenbach, Roland Penzel, Thomas Kremer, Christa Flechtenmacher, Burkhard Helmke, Jens Encke, Thomas Kraus, Peter Schirmacher – 23 September 2005 – Herpes virus hepatitis (HSV) represents a form of acute necrotizing hepatitis, which most frequently develops in immunocompromised patients. Therapeutic options include high‐dose intravenous acyclovir and liver transplantation. We report the first case of recurrent HSV hepatitis after liver retransplantation, which occurred despite continuous administration of high‐dose intravenous antiviral therapy.

Nanne K. H. de Boer, Chris J.J. Mulder, Adriaan A. van Bodegraven – 23 September 2005

Jens G. Brockmann, Christian August, Heiner H. Wolters, Ralf Hömme, Daniel Palmes, Hideo Baba, Hans‐U. Spiegel, Karl H. Dietl – 23 September 2005 – The impact of 3 different reperfusion sequences following orthotopic liver transplantation (OLT) in pigs were evaluated. The reperfusion technique commonly performed is primary portal in order to shorten warm ischemic times (WITs). Experimental and clinical data, usually comparing 2 out of 3 possible reperfusion sequences, provide controversial results.

Chih‐Che Lin, Feng‐Rong Chuang, Chih‐Hsiung Lee, Chih‐Chi Wang, Yaw‐Sen Chen, Yueh‐Wei Liu, Bruno Jawan, Chao‐Long Chen – 23 September 2005 – The purpose of this study is to find out whether basiliximab administration will improve postoperative renal function by delaying the start of tacrolimus and decreasing of dosage requirement for tacrolimus in adult living donor liver transplantation (LDLT). Forty‐five adult LDLT recipients were enrolled in the study.

Xiu‐Da Shen, Feng Gao, Bibo Ke, Yuan Zhai, Charles R. Lassman, Sei‐Ichiro Tsuchihashi, Douglas G. Farmer, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski – 23 September 2005 – The current models of liver ischemia/reperfusion injury (IRI) in mice are largely limited to a warm ischemic component. To investigate the mechanism of hepatic “cold” IRI, we developed and validated a new mouse model of prolonged cold preservation followed by syngeneic orthotopic liver transplantation (OLT).

Mark W. Russo, Roberto J. Firpi, David R. Nelson, Robert Schoonhoven, Roshan Shrestha, Michael W. Fried – 23 September 2005 – Recurrent hepatitis C after liver transplantation is a serious problem faced by liver transplant recipients. Activation of hepatic stellate cells is an early step in hepatic fibrogenesis. The aim of this study was to evaluate hepatic stellate cell activation, early after liver transplantation, as a predictor for the subsequent development of advanced fibrosis.

New York State Department of Health Workgroup – 23 September 2005

23 September 2005

Shin Hwang, Sung‐Gyu Lee, Jae‐Won Joh, Kyung‐Suk Suh, Dong‐Goo Kim – 23 September 2005 – Current selection criteria of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) were derived from the outcomes of cadaveric donor LT (CDLT). We tried to assess the applicability of such criteria to living donor LT (LDLT) through a comparative study between CDLT and LDLT. We analyzed the outcomes of 312 HCC patients who underwent LT at 4 Korean institutions during 1992 to 2002.